Study on the mechanism of Zhimu in the treatment of ovarian cancer based on network pharmacology

We aimed to investigate the mechanism of action of Zhimu in the treatment of ovarian cancer (OC) using network pharmacology. OC targets were screened using the DisGeNET and Online Mendelian Inheritance in Man databases. Common OC and Zhimu targets were identified using the Traditional Chinese Medicine System Pharmacology, UniProt databases, and Venny 2.1.0. The protein-protein interaction (PPI) network in the Search Tool for the Retrieval of Interacting Genes/Proteins database was created using Zhimu/OC targets and a Zhimu active ingredient-target-pathway network in the Cytoscape 3.9.1 software. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were conducted using the Metascape database. And overall, 15 active ingredients in addition to 93 related targets were identified. The PPI network had 52 targets that overlapped with it, with the 10 most relevant targets being the tumour protein p53, tumour necrosis factor, serine/threonine kinase 1, vascular endothelial growth factor A, caspase-3, prostaglandin G/H synthase-2, hypoxia-inducible factor-1 alpha, interleukin-1 beta, heat-shock protein 90-alpha, and progesterone receptor. According to GO and KEGG analyses, Zhimu and OC had the nuclear factor NF-kappaB signalling pathway, oxidative stress, and the advanced glycation end product (AGE)/the receptor for the advanced glycation end product (RAGE) signalling pathway as common targets. This study highlighted the active ingredients in Zhimu and identified potential molecular therapeutic mechanisms for the treatment of OC. It also provided suggestions and directions for future research into molecular mechanisms.

Cancer; Network pharmacology; Molecular mechanism; Zhimu

[1] Xiang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Medicine. 2019; 8: 1958–1975.

[2] Cui Y, Shu X-O, Gao Y, Wen W, Ruan Z-X, Jin F, et al. Use of complementary and alternative medicine by Chinese women with breast cancer. Breast Cancer Research and Treatment. 2004; 85: 263–270.

[3] Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO. The use of complementary and alternative medicine among Chinese women with breast cancer. Journal of Alternative and Complementary Medicine. 2008; 14: 1049–1055.

[4] Yu Y, Yan L, Wang X, Li L, Zheng W, Gao H. Study on the effects of Chinese materia medica processing on the hypoglycemic activity and chemical composition of anemarrhenae rhizoma. Evidence-Based Complementary and Alternative Medicine. 2021; 2021: 6211609.

[5] Han J, Yang N, Zhang F, Zhang C, Liang F, Xie W, et al. Rhizoma anemarrhenae extract ameliorates hyperglycemia and insulin resistance via activation of AMP-activated protein kinase in diabetic rodents. Journal of Ethnopharmacology. 2015; 172: 368–376.

[6] Ru J, Li P, Wang J, Zhou W, Li B, Huang C, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of Cheminformatics. 2014; 6: 13.

[7] Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nature Communications. 2019; 10: 1523.

[8] Penny SM. Ovarian cancer: an overview. Radiologic Technology. 2020; 91: 561–575.

[9] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Practice & Research. Clinical Obstetrics & Gynaecology. 2017; 41: 3–14.

[10] Yang S, Si L, Jia Y, Jian W, Yu Q, Wang M, et al. Kaempferol exerts anti-proliferative effects on human ovarian cancer cells by inducing apoptosis, G0/G1 cell cycle arrest and modulation of MEK/ERK and STAT3 pathways. Journal of BUON: Official Journal of the Balkan Union of Oncology. 2019; 24: 975–981.

[11] Wang P, Zhang J, Xiong X, Yuan W, Qin S, Cao W, et al. Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells. Oncology Reports. 2019; 41: 2321–2328.

[12] Guo X, Ding X. Dioscin suppresses the viability of ovarian cancer cells by regulating the VEGFR2 and PI3K/AKT/MAPK signalling pathways. Oncology Letters. 2018; 15: 9537–9542.

[13] Gu P, Su Y, Guo S, Teng L, Xu Y, Qi J, et al. Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation. Cancer Investigation. 2008; 26: 822–829.

[14] Chu S-H, Liu Y-W, Zhang L, Liu B, Li L, Shi J-Z, et al. Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Molecular Biology Reports. 2013; 40: 1–6.

[15] Ediriweera MK, Tennekoon KH, Samarakoon SR. Role of the PI3K/AKT/mTOR signalling pathway in ovarian cancer: biological and therapeutic significance. Seminars in Cancer Biology. 2019; 59: 147–160.

[16] Waghela BN, Vaidya FU, Ranjan K, Chhipa AS, Tiwari BS, Pathak C. AGE-RAGE synergy influences programmed cell death signalling to promote cancer. Molecular and Cellular Biochemistry. 2021; 476: 585–598.

[17] Yang W, Liu L, Li C, Luo N, Chen R, Li L, et al. TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway. Cell Death & Disease. 2018; 9: 908.

[18] Li Y, Wang S, Li P, Li Y, Liu Y, Fang H, et al. Rad50 promotes ovarian cancer progression through NF‐κB activation. Journal of Cellular and Molecular Medicine. 2021; 25: 10961–10972.

[19] Wang X, Wang F, Zhang ZG, Yang XM, Zhang R. STK3 suppresses ovarian cancer progression by activating NF-κB signaling to recruit CD8+ T-cells. Journal of Immunology Research. 2020; 2020: 7263602.